Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Figure 3 | Diabetology & Metabolic Syndrome

Figure 3

From: Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease

Figure 3

Association between the malondialdehyde-modified low-density lipoprotein (MDA-LDL)/LDL cholesterol (C) ratio and the number of metabolic syndrome (MS) components. The MDA-LDL/LDL-C ratios were compared in patients with the indicated number of MS components. Data are expressed as means ± SD. Statistical analyses were performed by analysis of variance with Tukey-Kramer’s honestly significant difference test. *, p < 0.05 vs. 1, 2, or 3; **, p < 0.001 vs. 1, 2, or 3.

Back to article page